From worst-case to reality - Case studies illustrating tiered refinement of consumer exposure to cosmetic ingredients.

Aggregate Benzoic acid Cosmetics safety evaluation DMDM hydantoin Exposure Occurrence data Propyl paraben

Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 23 10 2022
revised: 03 06 2023
accepted: 12 06 2023
medline: 1 9 2023
pubmed: 11 7 2023
entrez: 10 7 2023
Statut: ppublish

Résumé

Consumer exposure to cosmetic ingredients is estimated in a tiered manner. Simple Tier1 deterministic aggregate exposure modelling generates a worst case estimate of exposure. Tier1 assumes that a consumer uses all cosmetic products concomitantly daily, at maximum frequency, and products always contain the ingredient at the maximum allowed % w/w concentration. Refining exposure assessment from worst case to more realistic estimates uses evidence from surveys of actual use levels of ingredients and Tier2 probabilistic models, where distributions of consumer use data can be applied. In Tier2+ modelling, occurrence data provides evidence of products on the market actually containing the ingredient. Three case studies are presented using this tiered approach to illustrate progressive refinement. The scale of refinements from Tier1 to Tier2+ modelling for the ingredients, propyl paraben, benzoic acid and DMDM hydantoin were: 0.492 to 0.026; 1.93 to 0.042 and 1.61 to 0.027 mg/kg/day exposure dose. For propyl paraben, moving from Tier1 to Tier2+ represents a refinement from 49-fold to 3-fold overestimate of exposure when compared to a maximum estimate of 0.01 mg/kg/day exposure seen in human studies. Such refinements from worst case to realistic levels of exposure estimation can be critical in the demonstration of consumer safety.

Identifiants

pubmed: 37429522
pii: S0273-2300(23)00104-6
doi: 10.1016/j.yrtph.2023.105436
pii:
doi:

Substances chimiques

propylparaben Z8IX2SC1OH
Parabens 0
Cosmetics 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105436

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors are employed by the Cosmetics Industry. C Alexander-White is an independent consultant in chemicals safety assessment who was commissioned by Cosmetics Europe specifically for this project as a specialist in cosmetics safety evaluation and scientific writer.

Auteurs

Sarah Tozer (S)

Procter & Gamble Technical Centres Ltd, Reading, RG2 0QE, UK.

Camilla Alexander-White (C)

MKTox & Co Ltd, c/o LB Group, 80 Compare Crescent, Ipswich, IP2 0EH, UK. Electronic address: ckaw@mktoxconsult.com.

Ripal Amin (R)

Avon Products International, 1 Avon Place, Suffern, NY, 10901, USA.

Françoise Audebert (F)

FEBEA, 137 Rue de l'Universite 75007, Paris, France.

Catherine Barratt (C)

Unilever Safety & Environmental Assurance Centre (SEAC), Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, UK.

John O'Brien (J)

Creme Global, 4th Floor, The Tower, Trinity Technology & Enterprise Campus, Grand Canal Quay, Dublin 2, Ireland.

Tim Burke (T)

Reckitt, Hull, UK.

Dagmar Bury (D)

Worldwide Safety Evaluation Department, L'Oreal Research and Innovation, 9 Rue Pierre Dreyfus, 92110, Clichy, France.

Hermine Dika Nguea (HD)

Worldwide Safety Evaluation Department, L'Oreal Research and Innovation, 9 Rue Pierre Dreyfus, 92110, Clichy, France.

Myrto Dimopoulou (M)

Reckitt, Hull, UK.

Sarah Farahmand (S)

Edgewell Personal Care, 75 Commerce Drive, Allendale, NJ, 07401, USA.

Sabrina Fritz (S)

Kao Germany GmbH, Pfungstädter Straße 98-100, 64297, Darmstadt, Germany.

Elisabeth Gerber (E)

Beiersdorf AG, Unnasrasse 48, D-20245, Hamburg, Germany.

Arianna Giusti (A)

Cosmetics Europe - The Personal Care Association, Avenue Herrmann-Debroux 40, B-1160, Brussels, Belgium.

William Goodwin (W)

Creme Global, 4th Floor, The Tower, Trinity Technology & Enterprise Campus, Grand Canal Quay, Dublin 2, Ireland.

Taryn Kirsch (T)

Procter & Gamble, Sulzbacher Str. 40, 65824, Schwalbach am Taunus, Germany.

Victor Oreffo (V)

Unilever Safety & Environmental Assurance Centre (SEAC), Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, UK.

Cronan McNamara (C)

Creme Global, 4th Floor, The Tower, Trinity Technology & Enterprise Campus, Grand Canal Quay, Dublin 2, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH